Aemetis, Inc. AMTX 深 沪
等待开盘 01-22 09:30:00 美东时间
1.49
-0.040
-2.61%
华盛通- 最 高1.60
- 今 开1.52
- 成交量 98.14万股
- 最 低 1.4109
- 昨 收 1.53
- 总市值 9422.91万
- 52周最高 3.66
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.22
- 委 比 -13.94%
- 总股本 6324.10万
- 历史最高 27.44
- 量 比 1.37
- 振 幅 12.36%
- 历史最低 0.152
- 每 手 1
- 风险率 0.53%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Aemetis Sells $17M in Clean Energy Tax Credits, Nets About $15M in Cash
Aemetis, Inc. (NASDAQ:AMTX), a renewable natural gas and renewable liquid fuels company focused on lower cost and reduced emissions products, today announced that its Aemetis Biogas LLC subsidiary received funds from the
2025-12-30 21:05
Aemetis Receives Funds from the Sale of $17 million of Federal Clean Energy Tax Credits
Aemetis Biogas LLC, a subsidiary of Aemetis, Inc., received $17 million from the sale of federal clean energy tax credits, including $12 million from a Section 48 ITC for constructing a dairy manure digester and $5 million from a Section 45Z PTC for renewable natural gas production in 2025. Net proceeds were $15 million after costs. Eric McAfee, Aemetis' Chairman and CEO, highlighted this as a significant step toward monetizing tax incentives and...
2025-12-30 13:00
Aemetis Receives Authority to Construct Air Permits for MVR Project at California Ethanol Plant
Aemetis has received permits for its mechanical vapor recompression (MVR) project at its Keyes ethanol plant, which is expected to boost annual cash flow by $32 million starting mid-2026. The project, funded by $19.7 million in grants, aims to reduce natural gas usage by 80%, lower carbon intensity, and increase tax credits. Completion is slated for Q2 2026, furthering Aemetis' decarbonization efforts and renewable fuel production in California.
2025-12-02 13:00
美股大行评级 | 高盛上调百度、美敦力、晶科能源等多只个股目标价；家得宝遭9家机构下调目标价；
今日重点评级关注：富国银行：维持Annexon"超配"评级，目标价从14美元升至27美元；瑞穗：上调Relmada Therapeutics评级至"跑赢大市"，目标价从1美元升至10美元
2025-11-20 10:28
Ascendiant Capital Maintains Buy on Aemetis, Lowers Price Target to $20
Ascendiant Capital analyst Edward Woo maintains Aemetis (NASDAQ:AMTX) with a Buy and lowers the price target from $21 to $20.
2025-11-19 18:28
Aemetis Q3 EPS $(0.37) Misses $(0.20) Estimate, Sales $59.190M Miss $87.035M Estimate
Aemetis (NASDAQ:AMTX) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.20) by 85 percent. This is a 2.63 percent increase over losses of $(0.38) per share from the same
2025-11-06 20:58
Aemetis to Review Third Quarter 2025 Financial Results on November 6, 2025
Aemetis, Inc. (NASDAQ: AMTX) invites investors to a conference call on Thursday, November 6, 2025, at 11 am PT to discuss its third quarter 2025 earnings. Participants can join via toll-free or international dial-in numbers (entry code 188767) or via webcast at https://www.webcaster5.com/Webcast/Page/2211/53150. Questions will be addressed during the Q&A session. A voice recording will be available until November 13, and the webcast will remain a...
2025-10-31 12:00
API reverses stance on bill to expand sales of E15 gasoline
The American Petroleum Institute said Tuesday it opposes legislation to expand year-round sales of E15 gasoline, marking a reversal for the prominent oil and gas trade group. The API said in a letter ...
2025-10-22 08:48
Aemetis Extends Redemption Date for Preferred Units
An update from Aemetis ( ($AMTX) ) is now available. On October 15, 2025, Aemet...
2025-10-22 05:29
美股大行评级 | 潜在涨幅4347.41%！Ascendiant Capital上调PAVmed目标价至20美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持PAVmed"买入"评级，目标价从19美元升至20美元；Ascendiant Capital：维持Plus Therapeutics"买入"评级，目标价从20.5美元升至21美元
2025-10-07 15:04
